Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sanofi is a global biopharmaceutical company headquartered in Paris, France, specializing in prescription medicines, vaccines, and consumer healthcare products. Its competitive position is bolstered by a diverse product portfolio including diabetes care products like Lantus and Dupixent for immunology, alongside a robust pipeline in oncology and rare diseases, primarily in Europe and North America.
Sanofi generates revenue through the sale of patented pharmaceuticals, vaccines, and over-the-counter products. The company benefits from strong pricing power due to its established brands and extensive R&D capabilities, which allow it to maintain a competitive edge in therapeutic areas with high unmet medical needs.
Approval and launch of new drugs, particularly in oncology and rare diseases
Market performance of key products like Dupixent and Lantus
Regulatory changes impacting drug pricing and reimbursement
M&A activity within the pharmaceutical sector
Regulatory changes that could affect drug pricing and market access
Technological disruption in drug development processes
Emergence of biosimilars that could erode market share of key products
Intense competition from other pharmaceutical companies in core therapeutic areas
Potential liabilities from litigation related to drug safety
Currency fluctuations impacting international revenues
moderate - As a healthcare company, Sanofi's performance is somewhat insulated from economic downturns, but overall healthcare spending can be influenced by GDP growth and consumer spending patterns.
Sanofi's financing costs are relatively low due to its strong balance sheet, but rising interest rates could impact consumer spending on healthcare products and affect valuations in the sector.
minimal - The company has a low debt-to-equity ratio of 0.27, indicating limited reliance on credit markets.
growth - due to strong pipeline and potential for new product launches driving future revenue growth.
moderate - historical beta indicates lower volatility compared to the broader market.
